Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System.
Stephen D SilbersteinShoshana ReshefJoshua M CohenSanjay GandhiMichael SeminerioVerena Ramirez CamposYoel KesslerStephen F ThompsonAndrew BlumenfeldPublished in: Advances in therapy (2022)
These results aid in supporting the safety profile of CGRP mAbs in the real-world setting and may provide clinicians and patients with additional insight when considering migraine preventive treatments.